Pelthos Therapeutics
PTHS
24 hedge funds and large institutions have $37.4M invested in Pelthos Therapeutics in 2026 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
95% more capital invested
Capital invested by funds: $19.2M → $37.4M (+$18.2M)
41% more funds holding
Funds holding: 17 → 24 (+7)
10.88% more ownership
Funds ownership: 27.19% → 38.07% (+11%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$8.45M |
| 2 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$574K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$516K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$386K |
| 5 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
+$266K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$317K |
| 2 |
CF
Cantor Fitzgerald
New York
|
-$84.7K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
-$40.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$16.4K |
| 5 |
AP
Aspect Partners
Fairfax,
Virginia
|
-$336 |
PTHS Hedge Fund Activity: Q2 2026 in Review
24 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Pelthos Therapeutics (PTHS) for Q2 2026, worth a combined $37.4M — up 95% from $19.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PTHS positions and 3 closed out — a net gain of 7 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $8.45M. The largest seller was J. Goldman & Co, cutting an estimated $317K.
- 24 institutional investors held Pelthos Therapeutics (PTHS) as of Q2 2026, up from 17 in Q1 2026.
- Funds reported $37.4M of Pelthos Therapeutics stock for Q2 2026, up 95% quarter-over-quarter.
- 10 funds opened new Pelthos Therapeutics positions in Q2 2026 and 3 closed out, a net change of +7 holders.
- The largest Pelthos Therapeutics buyer in Q2 2026 was AIGH Capital Management, an estimated $8.45M added.
- The largest Pelthos Therapeutics seller in Q2 2026 was J. Goldman & Co, an estimated $317K sold.
Based on aggregated 13F filings for Q2 2026.